Elevance Health (ELV) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is constructive but not a layup — consensus is a manageable bar (Q2 EPS ~$6.17 vs. management's implied ~$6.15 guide of ~23% of $26.75), yet the stock has already re-rated sharply (+30% since Q1 earnings), meaning any shortfall or guidance caution will be punished; the single biggest swing factor is whether Medicaid cost trends have continued to moderate or have re-accelerated into Q2.

Heading into Q2 2026 results, the bar for ELV is calibrated but not easy. Management guided Q2 EPS to approximately 23% of the raised full-year guide of at least $26.75, implying roughly $6.15 — consensus sits at $6.17, essentially in line with the midpoint, leaving little room for error but also limited downside from estimate cuts. The tone from Q1 was measured confidence: management raised full-year guidance by $1.25 while deliberately excluding $1.00 of non-recurring investment income from the 2027 growth baseline, a credibility-building signal the market rewarded. Estimate trajectory has been broadly stable post-Q1 raise, with the full-year consensus at ~$26.80 tracking just above the $26.75 floor — revisions are neither accelerating higher nor rolling over, suggesting the Street is waiting for Q2 execution proof before moving numbers. The stock has re-rated aggressively from $328 at Q1 earnings to $427 today (+30%), compressing the discount to peers and reducing the margin of safety; at ~16x NTM EPS, ELV is no longer the deep-value name it was in April, though it still trades at a discount to UNH and the sector. The wildcard is Medicaid cost trend: Q1 showed early evidence of cost moderation in behavioral health and specialty pharmacy, but management maintained a prudent full-year margin assumption of approximately -1.75% — if Q2 data confirms the trend is bending, there is upside to both the Q2 print and the full-year guide; if trend has re-accelerated, the stock faces a sharp reversal given how much has already been priced in.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar on EPS (essentially in line with management's implied guide), but the Medical Loss Ratio is the bigger swing factor — a Q2 MLR that comes in below the ~89.9% consensus would be the clearest signal that Medicaid and MA cost trends are genuinely improving, and would likely drive upward revisions to the full-year guide.

Table 1 — Q2 2026 Snapshot: Key KPIs

Source: Visible Alpha Consensus and Actuals Data. Q1 2026 actuals and Q2 2025 actuals from Visible Alpha. Q2 2026 consensus estimates from Visible Alpha as of July 14, 2026. FY 2026 consensus: $195.6B revenue, $26.80 EPS, $6.24B operating gain.

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Adj. EPS & MLR)

Pattern: ELV has beaten on Adj. EPS in 6 of the last 8 quarters, with the two misses (Q2 2025 and Q3 2024) both driven by MLR deterioration — the pattern underscores that cost trend is the primary earnings driver, and beats tend to cluster when claims experience is favorable. The Q1 2026 beat was the largest in the series (+18.1% on EPS), though partially inflated by non-recurring investment income.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance moved materially higher at Q1 2026 — full-year EPS raised to at least $26.75 from at least $25.50 — but management deliberately excluded $1.00 of non-recurring investment income from the 2027 baseline, signaling disciplined credibility-building rather than aggressive optimism; tone has shifted from cautious repositioning to measured confidence, with the key remaining uncertainty being Medicaid rate adequacy in the back half.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimate revisions have been broadly stable since the Q1 2026 guidance raise — the Street has absorbed the $26.75 floor and is sitting just above it at ~$26.80, suggesting neither aggressive upward revision nor meaningful skepticism; the lack of further upward revision despite the Q1 beat reflects the market's appropriate caution around the non-recurring NII component and the still-uncertain Medicaid back-half trajectory.

Source: Visible Alpha Consensus and Actuals Data; ELV Q1 2026 Earnings Call (April 22, 2026).

5. Stock Performance

Key Takeaway: ELV has surged +30.0% since Q1 2026 earnings (Apr 22 → Jul 14: $328.20 → $426.79), dramatically outperforming UNH (+20.3%), XLV (+8.1%), and SPY (+5.7%) — the stock has re-rated from deep-value to fair value, compressing the discount to peers and raising the bar for Q2 to sustain the move.

ELV vs. UNH, XLV (Health Care ETF), and S&P 500 — Indexed to 100 at Q1 2026 Earnings (Apr 22, 2026). Source: Stock Price Data.

Source: Stock Price Data. Returns computed close-to-close, Apr 22, 2026 → Jul 14, 2026.

Context: ELV's sharp outperformance reflects the market re-rating the stock from a deep-discount "show-me" story to a credible recovery narrative following the Q1 beat and guidance raise. The stock has closed much of the gap to UNH (ELV $427 vs. UNH $425 as of Jul 14), a notable shift from the wide discount that prevailed through most of 2025. At ~16x NTM EPS, ELV is no longer the obvious value trade — the stock now needs Q2 execution to justify the re-rating. The CMS compliance deadline of July 31, 2026 is an additional near-term catalyst that could either remove an overhang (if compliance is confirmed) or re-introduce uncertainty.

6. Peer Commentaries — Q2 2026 Read-Throughs

The following peer commentaries are drawn exclusively from Q1 2026 earnings calls and post-Q1 events (April–July 2026), which contain forward-looking commentary about Q2 2026 and the remainder of 2026. These are the relevant read-throughs for ELV's upcoming Q2 2026 print. Prior-quarter results commentary (i.e., peers discussing their own Q4 2025 results) has been excluded.

6.1 Humana (HUM) — Q1 2026 Earnings Call (April 29, 2026)

Read-Through Relevance: High for Medicare Advantage. HUM is the most direct MA peer and its Q2 cost trend commentary is the clearest signal for ELV's MA margin trajectory.

• Medicare Advantage cost trends: HUM affirmed its full-year 2026 adjusted EPS guidance, signaling that MA cost trends have not materially deteriorated from Q1 levels. This is a constructive read-through for ELV's MA margin target of at least 2% for FY 2026.
• Utilization environment: HUM's Q1 2026 results showed favorable claims experience relative to expectations, consistent with ELV's own Q1 commentary about lighter-than-expected flu season and improving claims trends. If this pattern held into Q2, it supports ELV's MLR guidance.
• MA membership: HUM has been executing a similar portfolio optimization strategy to ELV — exiting unprofitable geographies and focusing on D-SNP and value-based care aligned products. HUM's affirmation of guidance suggests the MA repositioning playbook is working across the sector.
• Key ELV implication: HUM's guidance affirmation is a green flag for ELV's MA margin recovery story. If HUM's Q2 2026 results (reporting July 29) show continued MA improvement, it would further validate ELV's at-least-2% MA margin target.

6.2 Centene (CNC) — Q1 2026 Earnings Call (April 28, 2026)

Read-Through Relevance: High for Medicaid. CNC is the largest pure-play Medicaid managed care company and its Q2 cost trend and rate adequacy commentary is the most direct read-through for ELV's Medicaid margin trajectory.

• Medicaid cost trends: CNC reported Q1 2026 results and provided forward guidance for Q2 and the full year. CNC's commentary on Medicaid rate adequacy and cost trend is directly relevant to ELV's Medicaid operating margin outlook of approximately -1.75% for FY 2026.
• Rate environment: CNC's Q1 2026 commentary on state rate negotiations and the pace of rate catch-up to trend is a key read-through. ELV noted that Medicaid rates are coming in close to the mid-single-digit range but slightly below trend — if CNC is seeing similar dynamics, it confirms the sector-wide rate adequacy challenge is not ELV-specific.
• Medicaid membership: CNC's commentary on eligibility reverifications and disenrollment activity is relevant to ELV's expectation of a high single-digit percentage decline in Medicaid membership for FY 2026. Consistent trends across peers would validate ELV's membership guidance.
• Key ELV implication: If CNC's Q2 2026 Medicaid MLR is tracking in line with or better than expectations, it is a positive read-through for ELV's Medicaid margin. Conversely, if CNC signals accelerating Medicaid cost trend, it raises risk for ELV's back-half assumptions.

6.3 CVS Health (CVS) — Q1 2026 Earnings Call (May 6, 2026)

Read-Through Relevance: Moderate for MLR and utilization trends. CVS's Aetna health insurance segment provides a read-through on commercial and Medicare utilization trends heading into Q2.

• Strong Q1 results and guidance raise: CVS reported strong Q1 2026 results and raised its full-year 2026 guidance, signaling that the broader managed care utilization environment in Q1 was favorable. This is consistent with ELV's own Q1 beat and guidance raise.
• Aetna MLR trends: CVS's Aetna segment commentary on Q2 MLR seasonality is a read-through for ELV's Q2 MLR expectation of ~89.9% (consensus). CVS noted that Q2 typically sees higher MLR than Q1 due to deductible seasonality — consistent with ELV's own Q2 cadence guidance.
• Commercial utilization: CVS's commentary on commercial risk utilization trends is relevant to ELV's Commercial & Specialty segment. Favorable commercial trends at CVS/Aetna would be a positive read-through for ELV's commercial margin.
• Key ELV implication: CVS's guidance raise and constructive Q2 outlook is a broadly positive read-through for the managed care sector heading into Q2 earnings season. It suggests the favorable claims environment that drove Q1 beats across the sector has not sharply reversed.

6.4 Cigna Group (CI) — Q1 2026 Earnings Call (April 30, 2026) & BofA Conference (May 13, 2026)

Read-Through Relevance: Moderate for commercial/employer trends and SG&A. CI's Cigna Healthcare segment is a direct commercial peer; its Q2 MCR and employer utilization commentary is relevant to ELV's commercial segment.

• Raised FY 2026 EPS guidance to at least $30.35: CI raised its full-year 2026 adjusted EPS outlook to at least $30.35, reflecting strong Q1 performance and disciplined execution. This is a positive sector read-through — the managed care earnings recovery narrative is intact across multiple companies.
• Q2 EPS cadence ~25% of full year: CI guided Q2 adjusted EPS to approximately 25% of the full-year outlook (~$7.59 implied). This is slightly more front-half weighted than ELV's 23% Q2 cadence, reflecting CI's different business mix (no Medicaid, divested Medicare).
• Q2 MCR expected slightly above high end of full-year range: CI explicitly guided Q2 medical care ratio to be "slightly above the high end of the full year range" of 83.7%–84.7%, reflecting typical seasonality. This is a direct read-through for ELV's Q2 MLR — seasonal MLR step-up from Q1 to Q2 is a sector-wide pattern, not an ELV-specific risk.
• Steeper MCR seasonality due to Medicare divestiture: CI noted that its MCR seasonality will be steeper in 2026 because the divested Medicare business had flatter MCR seasonality. This is a useful context point — ELV's ACA Bronze plan mix shift is creating a similar steeper seasonality dynamic, which management has already guided for.
• ACA exchange exit announced: CI announced it will exit the individual exchange business at end of 2026, citing inability to scale to meaningful size. This is a modest positive for ELV's ACA business — one fewer competitor in the exchange market for 2027 open enrollment.
• Reaffirmed at BofA Conference (May 13): CI reaffirmed its 2026 adjusted EPS outlook of at least $30.35 at the BofA Securities Health Care Conference, signaling no deterioration in the business environment between Q1 earnings and mid-May. This is a positive read-through for ELV's Q2 setup.
• Key ELV implication: CI's constructive Q2 guidance and sector-wide MCR seasonality commentary validates ELV's own Q2 cadence guide. The ACA exit is a minor positive for ELV's 2027 exchange positioning.

6.5 Molina Healthcare (MOH) — Q1 2026 Earnings Call (April 23, 2026) & Investor Day (May 8, 2026)

Read-Through Relevance: High for Medicaid. MOH is a pure-play Medicaid managed care company and its Investor Day (May 8) provided the most detailed and forward-looking Medicaid commentary of any peer in the last 60 days — directly relevant to ELV's Medicaid margin recovery thesis.

• Managed Medicaid is underfunded by 300 bps sector-wide: MOH's CEO Joseph Zubretsky stated at Investor Day that "Managed Medicaid is underfunded by 300 basis points" across the market, based on a 1.5% pretax loss vs. an actuarial pricing target of 1.5%. This is a critical read-through for ELV — it confirms that ELV's Medicaid margin pressure is a sector-wide structural issue, not company-specific execution failure, and that rate catch-up is necessary and expected.
• Medicaid rates forecast to grow 4%–5%: MOH projected Medicaid rates to grow 4%–5% in its 3-year outlook. ELV noted Q1 rates coming in close to the mid-single-digit range — consistent with MOH's rate growth forecast. This validates ELV's expectation that rates are moving in the right direction, even if still slightly below trend.
• 2026 Medicaid same-store attrition increased to 6% (from 2%): MOH increased its 2026 Medicaid same-store attrition assumption from 2% to 6%, driven primarily by California, Illinois, and New York. This is a read-through for ELV's Medicaid membership guidance of a high single-digit percentage decline — the attrition is being driven by eligibility reverifications and the "One Big Beautiful Bill" (OBBB) work requirement provisions, which MOH expects to cause 2%–3% annual Medicaid membership decline over the next three years.
• OBBB work requirements: manageable but phased: MOH characterized the OBBB Medicaid work requirements as causing a 2%–3% annual membership decline over three years, with only a minor acuity shift. ELV's management made a similar point on the Q1 call — "much more phased and much more manageable than the redetermination cycle historically." Consistent messaging across peers reduces the tail risk of a sudden, sharp Medicaid membership cliff.
• Rate environment improving as 2024–2025 data enters baseline: MOH noted that "when 2024 and 2025 are in the baseline, the flexibility to misforecast trend is lower," pointing to a better rate environment ahead. This supports ELV's expectation of better rate alignment in 2027 as states incorporate recent experience into rate-setting cycles.
• MOH needs only 90 bps of improvement vs. market's 300 bps need: MOH framed its Medicaid recovery as requiring only 90 bps of margin improvement vs. the market's 300 bps need, positioning itself as better placed than peers. ELV's Medicaid margin target of approximately -1.75% for 2026 (trough) implies a similar multi-year recovery arc.
• Key ELV implication: MOH's Investor Day is the most important peer read-through for ELV's Medicaid story. The sector-wide underfunding confirmation, rate growth trajectory, and OBBB characterization all validate ELV's Medicaid narrative. The key risk is whether ELV's specific state mix (which may differ from MOH's California/Illinois/New York concentration) is seeing similar or worse attrition dynamics.

6.6 Peer Read-Through Summary Table

7. Material News & Developments (Since Q1 2026 Earnings)

Key Takeaway: The most material near-term catalyst is the CMS compliance deadline of July 31, 2026 — just 16 days after Q2 earnings — which management expects to resolve without sanctions going into effect; resolution would remove the single largest overhang on the stock.

• CMS Sanctions Compliance Deadline — July 31, 2026 (CRITICAL): ELV accrued approximately $935 million as its best estimate of identified potential exposure related to the CMS Medicare Advantage risk adjustment data submission dispute. The compliance deadline was extended to July 31, 2026. Management has expressed confidence that sanctions will not go into effect if compliance steps are completed. This is the single most important near-term binary event for the stock — resolution removes a major overhang; failure to comply would be a significant negative surprise.
• Q2 2026 Earnings Call Scheduled — July 15, 2026: ELV announced its Q2 2026 earnings call and webcast on July 6, 2026. The call is scheduled for July 15, 2026, one day after this preview was prepared.
• Shareholders Reject Political Contributions Study Proposal — May 13, 2026: ELV shareholders rejected a shareholder proposal requesting a study on political contributions at the annual meeting. This is a non-material governance item with no financial impact.
• Cigna Exits ACA Exchange Business — April 30, 2026: CI announced it will exit the individual exchange business at end of 2026. This is a minor positive for ELV's ACA positioning — one fewer competitor in the exchange market for 2027 open enrollment, potentially supporting ELV's ACA membership trajectory.
• MOH Investor Day — May 8, 2026: Molina Healthcare held an Investor Day presenting a 3-year outlook to 2029, targeting $25 EPS and $64B in premium revenue. The event provided the most detailed Medicaid sector commentary since Q1 earnings, validating the sector-wide rate adequacy challenge and the gradual recovery path. MOH's 2026 same-store Medicaid attrition assumption was raised from 2% to 6%.
• Molina Healthcare Shareholders Approve Equity Plan — May 11, 2026: MOH shareholders approved an equity plan boost and special meeting right. Non-material for ELV.
• CVS Health Raises FY 2026 Guidance — May 6, 2026: CVS reported strong Q1 2026 results and raised its full-year 2026 guidance, a positive sector read-through for the managed care utilization environment heading into Q2.
• Centene Appoints New Board Member — June 22, 2026: CNC appointed Lauren Tyler to its Board of Directors. Non-material for ELV.

8. Insider Transaction Activity

Key Takeaway: Insider activity since Q1 2026 earnings is dominated by routine annual director equity grants (May 13) and one small open-market sale by the CAO — there are no large discretionary insider purchases that would signal unusual management conviction, nor are there large open-market sales that would signal concern; the activity is consistent with normal course compensation and governance.

Source: Insider Transaction Data (SEC Form 4 filings). Filing dates: May 13 – June 15, 2026.

Analysis: The May 13 director grants are routine annual equity compensation and carry no informational signal. The June 11–12 open-market sales by Director Dixon (151 shares) and CAO Penczek (369 shares) are small in absolute terms relative to their total holdings (10,734 and 3,740 shares respectively) and are consistent with normal tax or liquidity management. Notably, there are no large discretionary open-market purchases by senior executives or directors — which would have been a stronger positive signal — but the absence of large sales is also consistent with management's expressed confidence in the recovery trajectory. The insider picture is neutral-to-slightly-positive: no red flags, no strong conviction signal.

Appendix: Key Risks to Watch

• Medicaid cost trend re-acceleration: If Q2 Medicaid MLR comes in above the ~-1.75% FY margin assumption, it would force a guidance cut and likely reverse a significant portion of the stock's post-Q1 gains. This is the primary downside risk.
• CMS sanctions resolution failure: If ELV fails to complete compliance steps by the July 31, 2026 deadline, CMS sanctions could go into effect, creating financial and reputational risk beyond the $935M accrual. Management has expressed confidence this will not occur, but it remains a binary event.
• ACA Bronze plan seasonality: The shift toward Bronze plans creates steeper Q2 seasonality (higher MLR in Q2 vs. Q1). If the seasonality is more pronounced than guided, Q2 EPS could miss the ~23% cadence target.
• Carelon leadership transition execution: Mark Kaye's assumption of Carelon oversight following Pete Haytaian's departure is a leadership change mid-year. Any execution disruption in Carelon's external revenue growth would be a negative surprise.
• OBBB Medicaid work requirements: While management and peers characterize the impact as manageable and phased, any acceleration in Medicaid membership attrition beyond the high single-digit guidance range would pressure both revenue and margins.
• Stock re-rating risk: At ~16x NTM EPS and +30% since Q1 earnings, ELV has limited valuation cushion. Any guidance miss or cautious tone on the Q2 call could trigger a sharp reversal given how much has already been priced in.